Publications by authors named "M Schell"
Background: Over a century ago, Virchow proposed that cancer represents a chronically inflamed, poorly healing wound. Normal wound healing is represented by a transitory phase of inflammation, followed by a pro-resolution phase, with prostaglandin (PGE2/PGD2)-induced 'lipid class switching' producing inflammation-quenching lipoxins (LXA4, LXB4).
Objective: We explored if lipid dysregulation in colorectal cancers (CRCs) is driven by a failure to resolve inflammation.
A healthy metabolism relies on precise regulation of anabolic and catabolic pathways. While insulin deficiency impairs anabolism, insulin resistance in obesity causes metabolic dysfunction, especially via altered brain insulin receptor (IR) activity. Density-enhanced phosphatase 1 (DEP-1) negatively modulates the IR in peripheral tissues.
View Article and Find Full Text PDFArticle Synopsis
- Researchers developed new photoconductive, continuous wave THz detectors using rhodium-doped InGaAs that are excited by 1550 nm light.
- Rh-doped InGaAs shows better carrier mobility compared to iron-doped materials, leading to a significant 10-fold increase in responsivity and noise-equivalent-power while keeping the same bandwidth.
- The new detectors achieved a record peak dynamic range of 132 dB in a homodyne spectrometer setup, improving by 20 dB over previous technologies.
Oral human papillomavirus (HPV) is associated with oropharyngeal cancer (OPC). Although OPC incidence is increasing globally, knowledge of oral HPV infection rates is limited. Here we carried out an observational epidemiological analysis of oral HPV incidence in 3,137 men enrolled from the United States, Mexico and Brazil between 2005 and 2009.
View Article and Find Full Text PDFArticle Synopsis
- This study investigates the use of intratumoral tavokinogene telseplasmid (TAVO-EP) with nivolumab before surgery in patients with advanced melanoma, focusing on its effects on the tumor environment.
- Sixteen patients participated, showing a 63% preoperative response rate, with a pathologic complete response (pCR) of 60% and a major pathologic response (MPR) of 80% post-treatment.
- The treatment demonstrated significant immune activation and a favorable safety profile, suggesting TAVO-EP combined with nivolumab may be an effective strategy for enhancing anti-tumor immunity in melanoma.